New insights into the pathogenesis and genetics of psoriatic arthritis

Nature Clinical Practice Rheumatology

Volumn 5, Issue 2, 2009, Pages 83-91

  Nograles, Kristine E ^a   Brasington, Richard D ^b   Bowcock, Anne M ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; HLA ANTIGEN CLASS 1; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

CELL PROLIFERATION; CHROMOSOME 4Q; CHROMOSOME 5Q; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; KERATINOCYTE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RISK FACTOR; SYNOVIOCYTE; T LYMPHOCYTE ACTIVATION;

ARTHRITIS, PSORIATIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-23; RISK FACTORS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 59849103894     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0987     Document Type: Review

References (90)

1. Gelfand JM et al. (2005) The prevalence of psoriasis in African Americans: Results from a population-based study. J Am Acad Dermatol 52: 23-26
2. Menter A et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58: 826-850
3. Zachariae H et al. (2002) Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82: 108-113
4. Tam LS et al. (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford) 47: 718-723
5. Neimann AL et al. (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55: 829-835
6. Gladman DD et al. (2003) HLA is a candidate region for psoriatic arthritis: Evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64: 887-889
7. Bhalerao J and Bowcock AM (1998) The genetics of psoriasis: A complex disorder of the skin and immune system. Hum Mol Genet 7: 1537-1545
8. Myers A et al. (2005) Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford) 44: 773-776
9. Rahman P and Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 (suppl 2): 37-39
10. Griffiths CE and Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271
11. Palazzi C et al. (2005) Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 53: 223-225
12. Moll JM and Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55-78
13. Taylor W et al. (2006) Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 54: 2665-2673
14. Gladman DD et al. (2005) Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (suppl 2): 14-17
15. Myers WA et al. (2006) Psoriasis and psoriatic arthritis: Clinical features and disease mechanisms. Clin Dermatol 24: 438-447
16. McGonagle D (2005) Imaging the joint and enthesis: Insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 64 (suppl 2) 58-60
17. Nash P and Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64 (suppl 2): 74-77
18. Gottlieb A et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58: 851-864
19. Warren RB and Griffiths CE (2008) Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 26: 438-447
20. Chan ES and Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4: 266-273
21. Mease PJ (2006) Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 54: 1638-1645
22. Dubertret L et al. (2006) Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebocontrolled trial. Br J Dermatol 155: 170-181
23. Papp KA et al. (2007) Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 11: 57-66
24. Myers WA et al. (2006) New-onset, debilitating arthritis in psoriasis patients receiving efalizumab. J Dermatolog Treat 17 353-354
25. Mease PJ and Antoni CE (2005) Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 64 (suppl 2): 78-82
26. Fantuzzi F et al. (2008) Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 12 1085-1096
27. Zaba LC et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-3194
28. Collamer AN et al. (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 59: 996-1001
29. Leonardi CL et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674
30. Ritchlin C (2007) Psoriatic disease - from skin to bone. Nat Clin Pract Rheumatol 3: 698-706
31. Gladman DD et al. (1999) HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 60: 259-261
32. Tsunemi Y et al. (2002) Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 30 161-166
33. Nair RP et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78 827-851
34. Helms C et al. (2005) Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118: 466-476
35. Veal CD et al. (2002) Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 71: 554-564
36. Elder JT (2006) PSORS1: Linking genetics and immunology. J Invest Dermatol 126: 1205-1206
37. Liu Y et al. (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4: E1000041
38. Gladman DD and Farewell VT (2003) HLA studies in psoriatic arthritis: current situation and future needs. J Rheumatol 30: 4-6
39. Korendowych E and McHugh N (2005) Genetic factors in psoriatic arthritis. Curr Rheumatol Rep 7: 306-312
40. Ho PY et al. (2007) HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 66: 807-811
41. Reich K et al. (2007) TNF polymorphisms in psoriasis: Association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 56 2056-2064
42. Williams F et al. (2005) Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 66: 836-841
43. Nelson GW et al. (2004) Cutting edge: Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173: 4273-4276
44. Boulet S et al. (2008) A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. Aids 22: 1487-1491
45. Martin MP and Carrington M (2005) Immunogenetics of viral infections. Curr Opin Immunol 17: 510-516
46. Cargill M et al. (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-290
47. Huffmeier U et al. (2008) Genetic variants of the IL-23R pathway: Association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol [doi:10.1038/jid.2008.233]
48. Duerr RH et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463
49. Burton PR et al. (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39: 1329-1337
50. Nair RP et al.: Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet (in press)
51. Lee E et al. (2004) Increased expression of interleukin-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130
52. Szodoray P et al. (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46: 417-425
53. McGeachy MJ and Cua DJ (2008) Th17 cell differentiation: The long and winding road. Immunity 28: 445-453
54. Awasthi A et al. (2008) Interplay between effector Th17 and regulatory T cells. J Clin Immunol 28: 660-670
55. Lowes MA et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128: 1207-1211
56. Nograles K (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyteresponse pathways. Br J Dermatol 159: 1092-102
57. Krueger JG and Bowcock A (2005) Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 64 (suppl 2): 30-36
58. Veale D et al. (1993) Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 36: 893-900
59. + T lymphocytes in psoriatic arthritis. J Rheumatol 26: 1117-1124
60. Colucci S et al. (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 212: 47-55
61. Yago T et al. (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96
62. Gottlieb A (2008) Phase 2 study of ustekinumab, a human IL-12/23 monoclonal antibody, in psoriatic arthritis: ACR criteria component score response through week 36 [abstract #1102]. Arthritis Rheum 58 (suppl): S577
63. van Heel DA et al. (2007) A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39: 827-829
64. Todd JA et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857-864
65. Zhernakova A et al. (2007) Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 81: 1284-1288
66. Sawalha AH et al. (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67: 458-461
67. Krueger JG et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448-458
68. + regulatory T cell subsets. J Leukoc Biol 74: 471-478
69. Parrish-Novak J et al. (2002) Interleukin-21 and the IL-21 receptor: Novel effectors of NK and T cell responses. J Leukoc Biol 72: 856-863
70. Wei L et al. (2007) IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282 34605-34610
71. Zhou L et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967-974
72. Zhou L et al. (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORγt function. Nature 453: 236-240
73. Koenen HJ et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340-2352
74. Zaiss MM et al. (2007) TREG cells suppress osteoclast formation: A new link between the immune system and bone. Arthritis Rheum 56 4104-4112
75. Cookson W (2004) The immunogenetics of asthma and eczema: A new focus on the epithelium. Nat Rev Immunol 4: 978-988
76. Li Y et al. (2008) The 5q31 variants associated with psoriasis and Crohn's disease are distinct. Hum Mol Genet 17: 2978-2985
77. Ho P et al. (2005) Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 52: 3596-3602
78. Finnegan A et al. (1999) Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 163: 5383-5390
79. Albanesi C et al. (2007) IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced betadefensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 179: 984-992
80. + precursors. J Immunol 175 6107-6116
81. Musone SL et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062-1064
82. Thomson W et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39: 1431-1433
83. Plenge RM et al. (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39: 1477-1482
84. Rahman P et al. (2006) Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 54 2321-2325
85. Athanasou NA et al. (1991) Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens. J Clin Pathol 44: 664-666
86. + myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 126: 1590-1609
87. Nakae S et al. (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81: 1258-1268
88. Barrett JC et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962
89. Martin MP et al. (2002) Cutting edge: Susceptibility to psoriatic arthritis: Influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169: 2818-2822
90. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299-1320